RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
IRLAB Therapeutics Stock

IRLAB Therapeutics Market capitalization 2024

IRLAB Therapeutics Market capitalization

663.92 M SEK

Ticker

IRLAB A.ST

ISIN

SE0012675361

WKN

A2PLBE

In 2024, IRLAB Therapeutics's market cap stood at 663.92 M SEK, a 84.33% increase from the 360.17 M SEK market cap in the previous year.

The IRLAB Therapeutics Market capitalization history

YEARMarket Capitalization (undefined SEK)
20230.51
20221.86
20212.3
20201.59
20192.34
20181.68
20170.77
2016-
2015-

IRLAB Therapeutics Aktienanalyse

What does IRLAB Therapeutics do?

IRLAB Therapeutics AB was founded in Stockholm, Sweden in 2012 and is a biopharmaceutical company specializing in the development of drugs for neurodegenerative diseases. The company has an innovative business model based on the discovery, development, and commercialization of drug candidates for various diseases. The company specializes in developing new and effective treatment options for neurodegenerative diseases. IRLAB Therapeutics AB has an extensive network of partners, including scientific institutions, universities, and clinical trial centers. With this network, the company ensures that all research and development activities are conducted using the latest scientific and technological advancements. The company operates in two segments: research and development and commercialization. In the research and development segment, the company focuses on identifying and developing drugs for neurodegenerative diseases such as Parkinson's and Alzheimer's. The company works on a pipeline of drug candidates in various stages of development, using advanced technologies such as in-silico screening and in-vivo testing to identify and develop new drug candidates. The commercialization segment of the company mainly deals with the distribution of already approved drugs. The company specializes in bringing these medications to market in its target regions. The company is particularly focused on the drugs Systebol and IRL752. Systebol is a medication for the treatment of cold-like symptoms in pregnant women and is already approved in some countries around the world. IRL752 is a substance for the treatment of psychiatric disorders and is also marketed by IRLAB Therapeutics. The main product of IRLAB Therapeutics AB is currently P21, a drug candidate for the treatment of Parkinson's disease. This drug candidate is in phase II of clinical trials and has received Orphan Drug designation from both the FDA and EMA. The company regularly reports on the progress of the clinical trials and announces ongoing news about the results. IRLAB Therapeutics AB has a clear vision and mission based on providing innovative solutions for patients with neurodegenerative diseases. The company aims to improve the lives of millions of people worldwide through the development of new and effective medical solutions. The company relies on collaboration with global and regional partners and invests in advanced technologies to establish itself as an innovative and reliable partner in the pharmaceutical industry. IRLAB Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring IRLAB Therapeutics's Market Capitalization

IRLAB Therapeutics's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of IRLAB Therapeutics's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

IRLAB Therapeutics's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in IRLAB Therapeutics’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about IRLAB Therapeutics stock

What is the current IRLAB Therapeutics market capitalization?

The current market capitalization of IRLAB Therapeutics is 663.92 M SEK.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like IRLAB Therapeutics.

How has the market capitalization of IRLAB Therapeutics developed in recent years?

The market capitalization of IRLAB Therapeutics has increased/decreased by 84.33% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of IRLAB Therapeutics?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of IRLAB Therapeutics?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of IRLAB Therapeutics have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does IRLAB Therapeutics pay?

Over the past 12 months, IRLAB Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IRLAB Therapeutics is expected to pay a dividend of 0 SEK.

What is the dividend yield of IRLAB Therapeutics?

The current dividend yield of IRLAB Therapeutics is .

When does IRLAB Therapeutics pay dividends?

IRLAB Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of IRLAB Therapeutics?

IRLAB Therapeutics paid dividends every year for the past 0 years.

What is the dividend of IRLAB Therapeutics?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is IRLAB Therapeutics located?

IRLAB Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von IRLAB Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of IRLAB Therapeutics from 10/6/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.

When did IRLAB Therapeutics pay the last dividend?

The last dividend was paid out on 10/6/2024.

What was the dividend of IRLAB Therapeutics in the year 2023?

In the year 2023, IRLAB Therapeutics distributed 0 SEK as dividends.

In which currency does IRLAB Therapeutics pay out the dividend?

The dividends of IRLAB Therapeutics are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von IRLAB Therapeutics

Our stock analysis for IRLAB Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IRLAB Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.